235 related articles for article (PubMed ID: 30589736)
1. Can pimavanserin help patients with Parkinson disease psychosis?
de la Cruz J; Canal C
JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
[TBL] [Abstract][Full Text] [Related]
2. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Sahli ZT; Tarazi FI
Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
[TBL] [Abstract][Full Text] [Related]
4. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
5. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Norton JC; Chi-Burris K; Demos G
CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
[TBL] [Abstract][Full Text] [Related]
6. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K; Price DL; Bonhaus DW
Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
[TBL] [Abstract][Full Text] [Related]
8. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
10. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Majlath Z; Obal I; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin for Parkinson Disease Psychosis.
Mohanty D; Sarai S; Naik S; Lippmann S
Prim Care Companion CNS Disord; 2019 Apr; 21(2):. PubMed ID: 31050230
[No Abstract] [Full Text] [Related]
12. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
13. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Sellers J; Darby RR; Farooque A; Claassen DO
Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
[TBL] [Abstract][Full Text] [Related]
14. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
15. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Price DL; Bonhaus DW; McFarland K
Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Psychosis in Parkinson's disease and sudden death.
Kyle K; Bronstein JM
Parkinsonism Relat Disord; 2020 Oct; 79():127. PubMed ID: 32943345
[No Abstract] [Full Text] [Related]
17. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
[No Abstract] [Full Text] [Related]
18. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Panchal SC; Ondo WG
Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
20. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
